Drug delivery systems based on mesoporous silica nanoparticles for the management of hepatic diseases.
10.1016/j.apsb.2024.12.015
- Author:
Boyan LIU
1
;
Wenshi LIU
2
;
Miao XU
1
;
Tongyi ZHAO
1
;
Bingxin ZHOU
1
;
Ruilin ZHOU
1
;
Ze ZHU
1
;
Xuchun CHEN
2
;
Zhiye BAO
2
;
Keke WANG
3
;
Heran LI
1
Author Information
1. School of Pharmacy, China Medical University, Shenyang 110122, China.
2. Department of Organ Transplantation and Hepatobiliary, the First Hospital of China Medical University, Shenyang 110001, China.
3. Department of Pharmacy, the First Hospital of China Medical University, Shenyang 110001, China.
- Publication Type:Review
- Keywords:
Biocompatibility;
Drug delivery;
Hepatic diseases;
Hepatocellular carcinoma;
Liver disease treatment;
MSNs–liver interactions;
Mesoporous silica nanoparticles;
Surface modification
- From:
Acta Pharmaceutica Sinica B
2025;15(2):809-833
- CountryChina
- Language:English
-
Abstract:
The liver performs multiple life-sustaining functions. Hepatic diseases, including hepatitis, cirrhosis, and hepatoma, pose significant health and economic burdens globally. Along with the advances in nanotechnology, mesoporous silica nanoparticles (MSNs) exhibiting diversiform size and shape, distinct morphological properties, and favorable physico-chemical features have become an ideal choice for drug delivery systems and inspire alternative thinking for the management of hepatic diseases. Initially, we introduce the physiological structure of the liver and highlight its intrinsic cell types and correlative functions. Next, we detail the synthesis methods and physicochemical properties of MSNs and their capacity for controlled drug loading and release. Particularly, we discuss the interactions between liver and MSNs with respect to the passive targeting mechanisms of MSNs within the liver by adjusting their particle size, pore diameter, surface charge, hydrophobicity/hydrophilicity, and surface functionalization. Subsequently, we emphasize the role of MSNs in regulating liver pathophysiology, exploring their value in addressing liver pathological states, such as tumors and inflammation, combined with multi-functional designs and intelligent modes to enhance drug targeting and minimize side effects. Lastly, we put forward the problems, challenges, opportunities, as well as clinical translational issues faced by MSNs in the management of liver diseases.
